4DMedical Limited operates as a medical technology company in Australia and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.33|
|52 Week High||AU$1.12|
|52 Week Low||AU$2.70|
|1 Month Change||-13.07%|
|3 Month Change||-12.50%|
|1 Year Change||-48.85%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-16.35%|
Recent News & Updates
Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
|4DX||AU Healthcare Services||AU Market|
Return vs Industry: 4DX underperformed the Australian Healthcare Services industry which returned 45.9% over the past year.
Return vs Market: 4DX underperformed the Australian Market which returned 19.3% over the past year.
Stable Share Price: 4DX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 4DX's weekly volatility (7%) has been stable over the past year.
About the Company
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology that utilizes proven and patented mathematic models and algorithms to convert X-ray scans into quantitative data to enhance the capacity of physicians to manage patients with respiratory diseases and diseases of the lung. The company is also developing VQ (Perfusion), a diagnostic to scan and measure ventilation and perfusion; and Contrast Free Pulmonary Angiography (CFPA) products, as well as small animal ventilators and preclinical scanners.
4DMedical Fundamentals Summary
|4DX fundamental statistics|
Is 4DX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4DX income statement (TTM)|
|Cost of Revenue||AU$91.85k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.073|
|Net Profit Margin||-9,872.21%|
How did 4DX perform over the long term?See historical performance and comparison
Is 4DMedical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4DX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4DX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4DX is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: 4DX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4DX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4DX is overvalued based on its PB Ratio (4.7x) compared to the AU Healthcare Services industry average (3.8x).
How is 4DMedical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4DX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4DX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4DX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4DX's revenue (71.8% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: 4DX's revenue (71.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4DX is forecast to be unprofitable in 3 years.
How has 4DMedical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4DX is currently unprofitable.
Growing Profit Margin: 4DX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4DX is unprofitable, and losses have increased over the past 5 years at a rate of 43.9% per year.
Accelerating Growth: Unable to compare 4DX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4DX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: 4DX has a negative Return on Equity (-25.7%), as it is currently unprofitable.
How is 4DMedical's financial position?
Financial Position Analysis
Short Term Liabilities: 4DX's short term assets (A$85.8M) exceed its short term liabilities (A$8.2M).
Long Term Liabilities: 4DX's short term assets (A$85.8M) exceed its long term liabilities (A$1.1M).
Debt to Equity History and Analysis
Debt Level: 4DX is debt free.
Reducing Debt: 4DX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4DX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4DX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.3% each year
What is 4DMedical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4DX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4DX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4DX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4DX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4DX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Andreas Fouras, BEng, MEngSc(Res), Ph D., M.A.I.C.D., is Founder of 4Dx Limited and serves as its Chief Technology Officer since April 2021, Managing Director and Chief Executive Officer. Dr. Fouras se...
CEO Compensation Analysis
Compensation vs Market: Andreas's total compensation ($USD478.97K) is about average for companies of similar size in the Australian market ($USD551.68K).
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
Experienced Management: 4DX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: 4DX's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.2%.
4DMedical Limited's employee growth, exchange listings and data sources
- Name: 4DMedical Limited
- Ticker: 4DX
- Exchange: ASX
- Founded: 2012
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$391.674m
- Shares outstanding: 294.49m
- Website: https://www.4dmedical.com
Number of Employees
- 4DMedical Limited
- 468 St Kilda Road
- Suite 501
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 15:52|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.